BIODOL Therapeutics is a biotech company developing first-in-class compounds for treating chronic pain. It is based on the discovery by Biodol's scientists of the target FLT3, which is a master hub protein in the initiation and maintenance of neuropathic pain (Nature Communications 2018). Morevover, Biodol discovered that its FLT3 breakthrough platform will also help fighting the "Opioid Crisis" (patented but yet unpublished). Biodol has a series of FLT3 selective small-molecule extracellular antagonists. The Biodol's FLT3 technological Platform is worldwide protected by 5 patents.
Company Details
- Employees
- 7
- Founded
- -
- Address
- 165 Rue Denis Papin, Montarnaud,34570,france
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- biodol.eu
- HQ
- Montarnaud
Biodol Therapeutics Questions
Biodol Therapeutics's website is biodol.eu
Biodol Therapeutics's LinkedIn profile is https://fr.linkedin.com/company/biodol-therapeutics
Biodol Therapeutics has
7 employees.
View email and phone details for 7
employees at Biodol Therapeutics.
Biodol Therapeutics's industry is
Pharmaceutical Manufacturing
Biodol Therapeutics's top competitors are
Ciloa Sas,
Phost'in Therapeutics,
Cilcare,
Oxeltis,
Apmonia Therapeutics,
Surgimab Sas,
Mabqi,
Azelead,
Occical Therapeutics,
Nervosave Therapeutics.
Biodol Therapeutics's categories are Pharmaceutical Manufacturing
Biodol Therapeutics's founding year is 2015
